Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002009 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
A Phase 1 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002009: Completed Phase 1 study, sponsored by Sandoz.
NCT00002009 is a Phase 1 study that has completed, run by Sandoz. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002009, a Phase 1 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To determine the maximum tolerated dose (MTD) and toxicity of sargramostim (recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF) given by continuous intravenous infusion (CIV) in patients with leukopenia in association with AIDS virus infection. In addition, single dose and steady state pharmacokinetics will also be determined.
Interventions
- DRUG Sargramostim
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002009 record still lists
NCT00002009 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Sargramostim is the first listed.
NCT00002009 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002009 about?
NCT00002009 is a clinical study titled "A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia". To determine the maximum tolerated dose (MTD) and toxicity of sargramostim (recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF) given by continuous intravenous infusion (CIV) in patients with leukopenia in association with AIDS virus infection. In addition, single dose and steady s...
What is the current status of trial NCT00002009?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002009?
The interventions under investigation include: Sargramostim (DRUG).
Who is sponsoring clinical trial NCT00002009?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.